Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.

about

Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.

Item

http://www.wikidata.org/entity/Q39124885

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Application of prognostic scor ...... of a Brazilian public service.

@en

Application of prognostic scor ...... of a Brazilian public service.

@nl

type

Item

label

Application of prognostic scor ...... of a Brazilian public service.

@en

Application of prognostic scor ...... of a Brazilian public service.

@nl

prefLabel

Application of prognostic scor ...... of a Brazilian public service.

@en

Application of prognostic scor ...... of a Brazilian public service.

@nl

P1476

Application of prognostic scor ...... of a Brazilian public service.

@en

P2093

Auro Del Giglio

http://www.w3.org/2001/XMLSchema#string

Damila Cristina Trufelli

http://www.w3.org/2001/XMLSchema#string

Debora Rodrigues Bonito

http://www.w3.org/2001/XMLSchema#string

Luana Magalhães Navarro

http://www.w3.org/2001/XMLSchema#string

Patricia Weinschenker Bollmann

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Personalized management of essential thrombocythemia-application of recent evidence to clinical practice

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Target hematologic values in the management of essential thrombocythemia and polycythemia vera.

P304

647-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/1806-9282.62.07.647

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27925044

http://www.w3.org/2001/XMLSchema#string